ESALF - Eisai GAAP EPS of ¥147.86 revenue of ¥741.8B; initiates FY25 outlook
2024-05-15 09:24:14 ET
More on Eisai
- Eisai: All About Lenvima And Leqembi
- Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy
- Biogen’s Alzheimer's drug to cost $3.5B for Medicare in 2025: report
- Historical earnings data for Eisai
- Dividend scorecard for Eisai